Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Molecular Markers Predictive Response to Dose Dense Chemotherapy With Epirubicin and Docetaxel in Sequences for Locally Advanced Breast Cancer.

NCT00496795 is registered in ClinicalTrials.gov with University of Bergen as lead sponsor.

NCT NCT00496795
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00496795 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Molecular Markers Predictive Response to Dose Dense Chemotherapy With Epirubicin and Docetaxel in Sequences for Locally Advanced Breast Cancer.
Lead sponsor
University of Bergen
Phase
Phase 2
Overall status
Unknown status
Start date
September 30, 2007
Completion date
May 31, 2026
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stage iii breast cancer ajcc v7